
Best Practices in Gynecologic Oncology 2026
Advancing care in gynecologic oncology
GLOBAL LEARNING OBJECTIVES
At the end of this CPD activity, participants will be able to
-
assess their knowledge and practice in the management of gynecologic cancers in light of current evidence, recent guidelines, and discussions of complex clinical cases;
-
identify gaps between their current practice and best practices in gynecologic oncology, particularly with respect to the integration of biomarkers, the selection of multimodal treatments, innovative surgical approaches, and patients’ quality of life;
-
determine concrete and applicable practice improvement strategies to optimize personalized, safe, interdisciplinary, and equitable care for patients with gynecologic cancers.

The event program may be subject to minor changes at the discretion of the scientific committee.
SATURDAY, JUNE 13, 2026
7:30-8:00
Networking Breakfast
8:00-9:15
Advanced and Metastatic Endometrial Cancer
Learning Objectives
At the end of this session, participants will be able to:
-
integrate the FIGO 2024 classification, including molecular classification, into the assessment and management of advanced and metastatic endometrial cancer;
-
select personalized treatment strategies based on the patient’s clinical, pathological, and molecular profile;
-
recognize approaches that may reduce treatment-related toxicity and preserve quality of life in women with advanced and metastatic endometrial cancer.
Dr. Marie-Claude Renaud and Dr. Alexandra Sebastianelli, CHU de Québec
9:15-9:25
Post test
9:25-10:40
Vulvar Cancer
Learning Objectives
At the end of this session, participants will be able to:
-
analyze the indications for and limitations of multimodal therapeutic strategies in the treatment of vulvar cancer;
-
recognize the current and potential role of biomarkers in individualizing care;
-
determine approaches aimed at reducing treatment-related morbidity and improving patients’ quality of life.
Dr. Céline Lechartier, gynecologic oncologist, and Dr. Hugo Villeneuve, radiation oncologist, CIUSSS du Saguenay–Lac-Saint-Jean
10:40-10:50
Post test
10:50-11:20
Networking Break
11:20-12:35
Recurrent Ovarian Cancer: Platinum-Sensitive and Platinum-Resistant Disease
Learning Objectives
At the end of this session, participants will be able to:
-
compare treatment strategies according to whether recurrence is platinum-sensitive or platinum-resistant;
-
recognize biomarkers that are useful for treatment selection and for estimating therapeutic response;
-
identify strategies to overcome treatment resistance while taking patients’ quality of life into account.
Dr. Élizabeth Tremblay, gynecologic oncologist, CHUM
12:35-12:45
Post test
12:45-13:45
Lunch
13:45-15:00
Locally Advanced and Recurrent Cervical Cancer
Learning Objectives
At the end of this session, participants will be able to:
-
analyze the best multimodal treatment options for patients with locally advanced or recurrent cervical cancer;
-
integrate biomarkers and relevant clinical characteristics into treatment personalization;
-
recognize interventions that may reduce treatment-related morbidity and improve patients’ quality of life.
Dr. Paul Bessette, gynecologic oncologist, CHU Sherbrooke
15:00-15:10
Post test
15:10-16:25
Innovative Surgical Approaches and Ovarian Cancer
Learning Objectives
At the end of this session, participants will be able to:
-
assess the indications, benefits, and limitations of cardiophrenic lymph node resection in ovarian cancer cytoreduction;
-
analyze the technical principles and safety considerations associated with complex diaphragmatic surgery;
-
recognize the contribution of advanced technologies to the planning and performance of extensive cytoreduction.
Dr. Lucas Sideris
16:25-16:35
Post test
16:35-16:50
Networking Break
16:50-17:50
Tumour Board
Learning Objectives
At the end of this session, participants will be able to:
-
analyze, through complex clinical cases, optimal integrative strategies applicable in gynecologic oncology in 2026;
-
assess the contribution of an interdisciplinary approach to decision-making and care optimization;
-
identify organizational, clinical, or systemic limitations that influence the delivery of care to patients with gynecologic cancer and determine opportunities for improvement.
Dr. Léonie Dallaire-Nantel, CIUSSS du Saguenay–Lac-Saint-Jean
17:50-18:00
Post test
18:00
Closing Remarks
SPEAKERS
Paul Bessette, MD
Gynecologic Oncologist, Researcher and Full Professor
CIUSSS de l’Estrie – CHUS, Faculty of Medicine and Health Sciences, Université de Sherbrooke
Dr. Paul Bessette completed his medical studies, residency in obstetrics and gynecology, and fellowship in gynecologic oncology at Université de Montréal. Since 1995, he has practised as an obstetrician-gynecologist and gynecologic oncologist within the Estrie suprarregional interdisciplinary team for the fight against gynecologic cancers (ISEL-CCG), at the Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS). He is a Full Professor in the Department of Obstetrics and Gynecology at the Faculty of Medicine and Health Sciences of Université de Sherbrooke, where he also served as Head of the Gynecologic Oncology Service. A researcher and founding member of the Cancer: Biology, Prognosis and Diagnosis Axis at the CHUS Research Centre, he is also a founding member and former president of the Regroupement des gynécologues-oncologues du Québec (RGOQ). Profile: [https://www.usherbrooke.ca/recherche/fr/specialistes/details/paul.bessette](https://www.usherbrooke.ca/recherche/fr/specialistes/details/paul.bessette)

Alexandra Sebastianelli, MD
Gynecologic Oncologist
CHU de Québec – Université Laval
Dr. Alexandra Sebastianelli is a gynecologic oncologist at CHU de Québec – Université Laval, Hôtel-Dieu de Québec, where she has been practising since 2010. She obtained her degree in obstetrics and gynecology from Université Laval in 2008, before completing a fellowship in gynecologic oncology at Université de Montréal in 2010. In 2016, she also completed a microprogram in university pedagogy in health sciences at Université Laval. Dr. Sebastianelli plays a key role in the training and education of future physicians. She is the Director of the Gynecologic Oncology Fellowship Program at Université Laval and an AMCEL Associate Professor in the Department of Obstetrics and Gynecology at the same university. She has also made significant contributions to the Society of Gynecologic Oncology of Canada, where she served as a member of the Guidelines Committee from 2012 to 2021, and as Chair of the committee from 2019 to 2020. She currently chairs the Regroupement des gynécologues-oncologues du Québec (RGOQ) and is responsible for the MED-1223 course on the female reproductive system at Université Laval. In addition to her academic responsibilities, Dr. Sebastianelli is a principal investigator and co-investigator on several Phase 2 and 3 research protocols at CHU de Québec – Université Laval. Her main areas of interest include ovarian cancer, gestational trophoblastic disease and medical education, fields in which she contributes to the advancement of knowledge and clinical practice.

Elizabeth Tremblay, MD
Gynecologic Oncologist
CHUM
Elizabeth Tremblay completed her fellowship training in gynecologic oncology at the CHUM, then pursued a second clinical fellowship in peritoneal surgery at Dalhousie University. She joined the CHUM team as a gynecologic oncologist in 2023. Her clinical interests focus on the medical and surgical management of ovarian neoplasms.

Conflict of interest coming soon
Lucas Sideris, MD, FRCSC
General Surgical Oncologist, Associate Professor
Université de Montréal
Dr. Sideris completed his medical studies at Université Laval and obtained his MD in 1997. He completed his specialty training in general surgery at Université de Montréal and received his certification from the Royal College of Physicians and Surgeons of Canada in 2002. He then pursued postdoctoral training through a fellowship at the Gustave Roussy Institute in Paris, which he completed in 2004, and obtained a diploma in clinical carcinology from Université Paris XI. In 2011, he obtained certification as a general surgical oncologist from the Collège des médecins du Québec. His areas of interest and expertise include peritoneal surface malignancies, breast diseases, clinical research and surgical education. From 2016 to 2025, he served as Director of the Surgical Foundations Program at Université de Montréal. He is currently Director of Residency Programs for the Surgery and Obstetrics-Gynecology cluster at Université de Montréal, as well as Director of the provincial peritoneal surface malignancies network within the Programme québécois de cancérologie.

Marie-Claude Renaud, MD
Gynecologic Oncologist
CHU de Québec – Université Laval
Biography coming soon

Hugo Villeneuve
Radiation Oncologist
CIUSSS du Saguenay–Lac-Saint-Jean, Hôpital de Chicoutimi
Biography coming soon

Léonie Dallaire-Nantel, MD
Gynecologic Oncologist
Hôpital de Chicoutimi
Dr. Léonie Dallaire-Nantel is a gynecologic oncologist at CIUSSS du Saguenay–Lac-Saint-Jean. She completed her medical studies at Université Laval and her specialization in obstetrics and gynecology at Université de Sherbrooke. She also completed a two-year fellowship in gynecologic oncology at Université Laval. During her training, she took part in international clinical rotations in Senegal and Mali, and was also involved in various research projects and scientific publications.

Céline Lechartier, MD
Gynecologic Oncologist
CIUSSS du Saguenay–Lac-Saint-Jean
She is a specialist physician in gynecologic oncology and holds a State Diploma of Doctor of Medicine from Université de Nantes in France, obtained in 2017. Her thesis focused on advanced ovarian cancer (FIGO stage III) and the prognostic impact of retroperitoneal lymph node involvement. That same year, she also obtained her Diploma of Specialized Studies (DES) in obstetrics and gynecology, following a residency completed between 2012 and 2017. From 2017 to 2020, she practised in gynecologic oncology in France, developing clinical expertise in the management of gynecologic cancers. During this period, she also completed additional training through a Diploma of Complementary Specialized Studies (DESC) in oncology, which she obtained in 2020. Driven by a desire to broaden her skills and take on new international challenges, she then crossed the Atlantic to pursue subspecialty training in gynecologic oncology through a fellowship at Université Laval in Québec, Canada. This led to her certification by the Royal College in gynecologic oncology. Since 2024, she has been practising as a gynecologic oncologist in the Saguenay region, where she is actively involved in the care of patients with gynecologic cancers in a regional setting.

Scientific Committee
Sponsors
Become Our Partner
RGOQ is the partner of choice for healthcare organizations, hospitals, patient advocacy groups, pharmaceutical companies, and medical device manufacturers that share our vision and commitment. By partnering with us, you join a network of professionals and organizations dedicated to improving patient outcomes and advancing the field of gynecologic oncology.



.png)

